NCT06144749: A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

Sponsor: Hillhurst Biopharmaceuticals, Inc.. Phase: PHASE1. Conditions: Anemia, Sickle Cell